Compare Inovio Pharmaceuticals Inc (INO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B). The key difference: Stanley Black & Decker, Inc. is far larger — about 152.3× Inovio Pharmaceuticals Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.79% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SWK | |
|---|---|---|
Market Cap | $89.27M | $13.60B |
Sector | Health | — |
52-Week High | $2.87 | $94.12 |
52-Week Low | $1.05 | $62.12 |
Enterprise Value | $60.28M | $19.77B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Stanley Black & Decker (SWK) trades at $88.19, down 2.2% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.80 surpassing the $0.59 estimate. Fundamentals reveal a P/E of 35.86 and net income margin of 2.44%, while cash flow trends indicate stable operations. Recent news highlights strength in aerospace and automotive segments but notes weak Tools & Outdoor demand.
SWK offers value with a P/S of 0.87 and dividend yield appeal, but high debt and margin pressures pose risks. The consensus price target is $83.00, with 43% of analysts rating it a buy. Earnings growth and debt reduction are key catalysts, though sector headwinds and economic sensitivity remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
